Impact of COVID-19 on the Brain and Cognition

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Systems Neuroscience".

Deadline for manuscript submissions: closed (25 March 2024) | Viewed by 1904

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Medical Psychology, School of Medical Sciences, Universidad Nacional de Asunción, San Lorenzo 111454, Paraguay
2. Regional Institute of Health Research, Universidad Nacional de Caaguazú, Coronel Oviedo 050106, Paraguay
3. School of Health Sciences, Universidad Sudamericana, Pedro Juan Caballero 130112, Paraguay
Interests: medical psychology; biological psychiatry; psychodermatology; psychopharmacology; public mental health

E-Mail Website
Guest Editor
Department of Experimental Medicine, Medical School, University of Foggia, 71100 Foggia, Italy
Interests: social psychiatry; clinical psychiatry; psychopharmacology; cultural psychiatry; public mental health
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Impact of COVID-19 on Cognition: Unraveling the Complexities

The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, has unveiled a multifaceted impact on human health, transcending the realm of respiratory illness. Although initially recognized as a respiratory virus, evidence supports its intricate influence on cognitive function. This Special Issue aims to delve into the nuanced effects of COVID-19 on cognition and explore the underlying mechanisms and potential ramifications.

Evidence suggests that SARS-CoV-2 can infiltrate the central nervous system. The neuroinvasive potential of the virus raises concerns regarding cognitive repercussions. Individuals infected with COVID-19 have reported cognitive deficits such as attention lapses, memory impairment, and slowed information processing. These impairments could stem from the disruption of neuronal activity by the virus, leading to synaptic dysfunction and altered neural circuitry.

COVID-19-associated inflammation, often referred to as the "cytokine storm," might also affect cognition. The systemic immune response triggered by the virus can lead to inflammation in the brain, affecting the neurotransmitter systems that are critical for cognitive processes. This neuroinflammation may contribute to brain fog and mental fatigue, which are reported by many COVID-19 survivors.

Furthermore, hypoxia resulting from severe respiratory distress may have a profound effect on cognition. Oxygen deprivation compromises brain function, particularly in the regions responsible for higher-order cognitive tasks. Even mild cases of COVID-19, involving respiratory symptoms, can lead to transient hypoxia, potentially contributing to cognitive fluctuations.

The psychological toll of the pandemic also intersects with cognition. The prolonged stress, anxiety, and social isolation associated with COVID-19 can detrimentally affect cognitive domains such as attention, working memory, and decision-making. Chronic stress triggers the release of cortisol, affecting the hippocampus and prefrontal cortex, which are crucial for learning and memory.

Longitudinal studies are essential for discerning the lasting cognitive consequences of COVID-19. "Long COVID" cases, where symptoms persist for months, often include cognitive impairments. Hence, understanding the trajectory of cognitive recovery or decline after infection is pivotal for devising targeted interventions.

In conclusion, COVID-19's impact on cognition involves a complex interplay of direct neuroinvasion, neuroinflammation, hypoxia, and psychosocial factors. The potential of the virus to alter neural pathways and disrupt cognitive processes underscores the need for comprehensive research. As the world navigates this unprecedented crisis, unraveling the intricacies of COVID-19's cognitive effects holds promise for informed healthcare strategies and interventions, ensuring holistic recovery for those affected.

Prof. Dr. Julio Torales
Dr. Antonio Ventriglio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19
  • cognition
  • neuroinvasion
  • neuroinflammation
  • cognitive deficit

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 417 KiB  
Article
Physical and Mental Health Characteristics of Hospitalized COVID-19 Patients with and without Type 2 Diabetes Mellitus in Turkey
by Abdulbari Bener, Murat Atmaca, Abdulla O. A. A. Al-Hamaq and Antonio Ventriglio
Brain Sci. 2024, 14(4), 377; https://doi.org/10.3390/brainsci14040377 - 13 Apr 2024
Viewed by 752
Abstract
The aim of this study was to assess the rates of depression, anxiety, and stress and quality of sleeping among COVID-19 patients with and without type 2 diabetes mellitus (T2DM). A case and control design has been employed, involving patients affected by COVID-19 [...] Read more.
The aim of this study was to assess the rates of depression, anxiety, and stress and quality of sleeping among COVID-19 patients with and without type 2 diabetes mellitus (T2DM). A case and control design has been employed, involving patients affected by COVID-19 infection (884 with T2DM vs. 884 controls without T2DM) and hospitalized in Istanbul (Turkey) from January to December 2021. A multivariate stepwise regression approach was used to test the associations between sociodemographic, metabolic, serum markers, mental health scores, and T2DM/COVID-19 patients’ clinical presentation. A statistically significant difference between T2DM and non-T2DM was found with respect to age, gender, BMI (body mass index), smoking, physical exercise, and physical comorbidities as well as levels of depression, anxiety, stress, and sleeping disorders (0.0003 ≤ all p = 0.025). With regard to serum biomarkers, vitamin D and ferritin were identified as useful parameters of reduction of glycated hemoglobin as well as COVID-19 infection among T2DM patients. This study detected that 25% of patients with COVID-19 and T2DM experienced mental distress, with sleeping disturbances and lifestyle changes markedly impacting their clinical outcome alongside metabolic and serum parameters. Full article
(This article belongs to the Special Issue Impact of COVID-19 on the Brain and Cognition)
Show Figures

Graphical abstract

12 pages, 1071 KiB  
Article
Co-ultraPEALut in Subjective Cognitive Impairment Following SARS-CoV-2 Infection: An Exploratory Retrospective Study
by Valentina Cenacchi, Giovanni Furlanis, Alina Menichelli, Alberta Lunardelli, Valentina Pesavento and Paolo Manganotti
Brain Sci. 2024, 14(3), 293; https://doi.org/10.3390/brainsci14030293 - 20 Mar 2024
Viewed by 755
Abstract
Neurological involvement following coronavirus disease 19 (COVID-19) is thought to have a neuroinflammatory etiology. Co-ultraPEALut (an anti-inflammatory molecule) and luteolin (an anti-oxidant) have shown promising results as neuroinflammation antagonists. The aim of this study was to describe cognitive impairment in patients with post-COVID-19 [...] Read more.
Neurological involvement following coronavirus disease 19 (COVID-19) is thought to have a neuroinflammatory etiology. Co-ultraPEALut (an anti-inflammatory molecule) and luteolin (an anti-oxidant) have shown promising results as neuroinflammation antagonists. The aim of this study was to describe cognitive impairment in patients with post-COVID-19 treated with co-ultraPEALut. The Montreal Cognitive Assessment (MoCA), the Prospective–Retrospective Memory Questionnaire (PRMQ), the Fatigue Severity Scale (FSS), and a subjective assessment were administered at baseline and after 10 months. Patients treated with co-ultraPEALut were retrospectively compared with controls. Twenty-six patients treated with co-ultraPEALut showed a significant improvement in PRMQ (T0: 51.94 ± 10.55, T1: 39.67 ± 13.02, p < 0.00001) and MoCA raw score (T0: 25.76 ± 2.3, T1: 27.2 ± 2, p 0.0260); the MoCA-adjusted score and the FSS questionnaires also showed an improvement, even though it was not statistically significant; and 80.77% of patients reported a subjective improvement. In the control subjects (n = 15), the improvement was not as pronounced (PRMQ T0: 45.77 ± 13.47, T1: 42.33 ± 16.86, p 0.2051; FSS T0: 4.95 ± 1.57, T1: 4.06 ± 1.47, p 0.1352). Patients treated with co-ultraPEALut and corticosteroids were not statistically different from those treated with co-ultraPEALut alone. Neuro-post-COVID-19 patients treated with co-ultraPEALut scored better than controls in MoCA and PRMQ questionnaires after 10 months: this may support the importance of neuroinflammation modulation for neuro-long-COVID-19. Full article
(This article belongs to the Special Issue Impact of COVID-19 on the Brain and Cognition)
Show Figures

Figure 1

Back to TopTop